Planning and Evaluation ABSTRACT Under the leadership of the Director, Brian Druker, rigorous planning and evaluation efforts continue to be a critical activity, focused on the ongoing growth and development of the OHSU Knight Cancer Institute (Knight). Druker shares the responsibility for establishing the vision and strategic plans with the Knight Senior Leadership composed of Tomasz Beer, M.D. (Deputy Director and Interim Associate Director Clinical Research), Lisa Coussens, Ph.D. (Associate Director Basic Research), Sara Courtneidge, Ph.D. (Associate Director Translational Research), Joe Gray, Ph.D. (Associate Director Biophysical Oncology), Ray Bergan, M.D. (Associate Director Medical Oncology), Kristin Bialobok, M.S.N (Associate Director Administration), and Mary Stenzel-Poore, Ph.D. (School of Medicine Associate Dean, Research). This group, together with external advisors, undertook extensive strategic planning and evaluation efforts with the goal of enhancing the productivity of our center. Three committees are responsible for the internal governance of the Knight: the Associate Directors Advisory Group, the Program Leaders and Shared Resource Directors Committee, and the Clinical Executive Group. These committees are structured to ensure successful operation of the Knight, support new initiatives and to promote interactions within and between programmatic elements of the Knight. The External Advisory Board (EAB) is a distinguished group of cancer specialists and is chaired by Dr. Joseph Simone. The EAB reviews the Knight's scientific progress, vision, and future plans. Further ad hoc discussions may occur between the Director and EAB members throughout the year. The EAB reviews the organizational structure, programs, and shared resources providing advice regarding whether each is adding value to the institute's mission. They evaluate scientific excellence, focus, and interactivity of each program. The EAB provides formal reports to the Director, which are shared with the OHSU President and Dean of the SOM. The recommendations of this group have been essential in developing our current leadership and program structure, and shared resources. The EAB has consistently helped us develop a programmatic structure that optimally aligns with the strengths of our institute, optimizes the capacity of programs to create trans-disciplinary studies, and supports inter-programmatic interactions. To engage the Knight membership in strategic planning, and to stimulate intra- and inter-programmatic member interactions, routine programmatic meetings, as well as a number of Knight-wide and programmatic retreats were held. Development Funds, in the form of pilot project awards, were provided to stimulate collaborative publications and multi-investigator grants. This investment and planning has successfully resulted in an overall member collaborative publication rate of 39%, as well as a significant increase in multi-investigator grants.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oregon Health and Science University
United States
Zip Code
Krey, Jocelyn F; Scheffer, Deborah I; Choi, Dongseok et al. (2018) Mass spectrometry quantitation of proteins from small pools of developing auditory and vestibular cells. Sci Data 5:180128
Rozanov, Dmitri V; Rozanov, Nikita D; Chiotti, Kami E et al. (2018) MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection. J Proteomics 176:13-23
Winters-Stone, Kerri M; Wood, Lisa J; Stoyles, Sydnee et al. (2018) The Effects of Resistance Exercise on Biomarkers of Breast Cancer Prognosis: A Pooled Analysis of Three Randomized Trials. Cancer Epidemiol Biomarkers Prev 27:146-153
Pennock, Nathan D; Martinson, Holly A; Guo, Qiuchen et al. (2018) Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J Immunother Cancer 6:98
Xu, Li; Gordon, Ryan; Farmer, Rebecca et al. (2018) Precision therapeutic targeting of human cancer cell motility. Nat Commun 9:2454
Chen, Emerson Y; Blanke, Charles D; Haller, Daniel G et al. (2018) A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. Am J Clin Oncol 41:1193-1198
Lane, Ryan S; Femel, Julia; Breazeale, Alec P et al. (2018) IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 215:3057-3074
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019

Showing the most recent 10 out of 277 publications